Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer.
High expression of prostate stem cell antigen (PSCA) has been shown to be associated with adverse prognostic features in clinically-diagnosed prostate cancer. The aim of this study is to analyze PSCA expression in cystoprostatectomies with incidental prostate carcinoma (PCa). PSCA expression was evaluated immunohistochemically in normal-looking epithelium (NEp), high-grade prostatic intraepithelial neoplasia (HGPIN) and pT2a Gleason score 6 acinar adenocarcinoma. The evaluation was carried out on 20 cystoprostatectomies (CyPs) with incidental PCa from men with bladder urothelial carcinoma (UC), and 20 radical prostatectomies (RPs) with hormonally untreated PCa from men with clinically detected PCa. Ki-67 was also investigated. The percentages of PSCA positive cells in HGPIN were significantly higher than in NEp (NEp: CyP, mean 2.92%+/-standard deviation 6.26%; RP, 3.5%+/-6.46%. HGPIN: CyP, 13.67%+/-12.78%; RP, 14.67%+/-11.34%) (p<0.001). The proportions of positive cells in PCa were greater than in HGPIN (CyP, 20.25%+/-15.96%; RP, 22.58%+/-13.67%) (p<0.001). For Ki-67 labeling, the proportions of positive nuclei in the CyPs significantly increased from NEp through HGPIN to PCa. A similar trend was seen in the RPs. In the CyPs the percentages of PSCA and Ki67 positive cells were lower than in the RPs, the differences between the CyP and RP compartments being not statistically significant. Our findings suggest that PSCA is a marker associated with neoplastic transformation of prostate cells, both in CyPs and RPs. However, there are no significant differences between CyPs with incidental prostate carcinoma and RPs with clinically diagnosed cancer.
Mazzucchelli
R
R
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
Barbisan
F
F
Santinelli
A
A
Lopez-Beltran
A
A
Cheng
L
L
Scarpelli
M
M
Montironi
R
R
D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D018267:Carcinoma, Acinar Cell / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D002471:Cell Transformation, Neoplastic / Q000276:immunology; D058851:GPI-Linked Proteins; D006801:Humans; D007150:Immunohistochemistry; D033162:Incidental Findings; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D011468:Prostatectomy; D019048:Prostatic Intraepithelial Neoplasia / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery
D000951:Antigens, Neoplasm; D058851:GPI-Linked Proteins; D019394:Ki-67 Antigen; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C110843:PSCA protein, human